The Cigna Group (CI) Stock Analysis 2026

HealthcareHealthcare Plans
$298.41
as of 2026-10-29
-5.5% (52-week)50D MA $283.29  |  200D MA $279.32

BriMind AI Score

Proprietary
53
Neutral
Price CAGR
10.4%
1Y Return
+1.7%
Analyst Upside
+11.2%
Rev Growth
6.7%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

CI Revenue & Profitability Breakdown

This chart shows how CI's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$282.38B
Cost of Revenue
-$256.58B
Gross Profit
$25.80B9.1% margin
Operating Expenses
-$14.55B
Operating Income
$11.25B4.0% margin
Tax & Other
-$4.84B
Net Income
$6.42B2.3% margin
Gross Margin
9.1%
Operating Margin
4.0%
Net Margin
2.3%

Key Financial Metrics

The Cigna Group trades at a trailing P/E of 11.53x, generates $7.98B in free cash flow, runs a debt/equity ratio of 74.29, and converts shareholder equity into profit at a 16.8% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$73.69B
P/E (Trailing)
11.53
P/E (Forward)
8.33
PEG Ratio
0.84
Revenue
$282.38B
Revenue Growth
6.7%
Earnings Growth
10.2%
Gross Margin
9.1%
Operating Margin
4.0%
Net Margin
2.3%
Return on Equity
16.8%
Return on Assets
4.5%
Free Cash Flow
$7.98B
Debt / Equity
74.29
Current Ratio
0.85
Quick Ratio
0.69
Beta
0.32
Dividend Yield
2.2%
Payout Ratio
25.4%
Insider Ownership
1.4%
Inst. Ownership
92.3%
Short % Float
2.2%
Book Value / Share
$161.62

Wall Street Analyst Consensus

Wall Street analysts covering The Cigna Group currently haven't converged on a clear consensus rating, with a mean 12-month price target of $341.42 (+14.4% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$341.42+14.4% upside

Technical Price Signals

CI is currently in a golden cross pattern, trading above its 50-day average of $283.29 and above its 200-day average of $279.32. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$298.41
50-Day MA
$283.29
▲ Price above
200-Day MA
$279.32
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal
Read the full CI in-depth report
Seven-method valuation, AI Score, blended price target, and a 5-year Monte Carlo simulation for CI.

Compare CI with Peers

CNC vs CICentene vs Cigna — Government Managed Care vs Diversifi
CI vs UNHCigna vs UnitedHealth — Health Insurer Comparison
CI vs HUMCigna vs Humana — Which Managed Care Stock Wins?
CVS vs CICVS Health vs Cigna — Pharmacy & PBM vs Diversified Hea
ELV vs CIElevance Health vs Cigna — Which Health Insurer Is the
CI vs MOHCigna vs Molina Healthcare — Which Health Insurer Is th

Further Reading

Research and guides that put CI’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

Risk ManagementHow to Build Your First Investment Portfolio: Risk Tolerance, Asset Allocation & Your First 5 FundsFundamentalsWarren Buffett Retired 2026: Berkshire Portfolio Under Greg AbelBeginnerWhat Is an AI Stock Score? How BriMindInvest Ranks StocksMarket TheoryStock Market Seasonality: Monthly Returns, 'Sell in May,' and What History Says

More Healthcare Stock Analysis

In-depth reports on companies operating alongside CI — business models, bull and bear cases, and the metrics that matter.

HUMHumana Inc.Healthcare PlansCVSCVS Health CorporationHealthcare PlansUNHUnitedHealth Group IncorporatedHealthcare PlansMOHMolina Healthcare, Inc.Healthcare PlansMCKMcKesson CorporationMedical DistributionCRSPCRISPR Therapeutics AGBiotechnologyALGNAlign Technology, Inc.Medical Instruments & SuppliesHCAHCA Healthcare, Inc.Medical Care Facilities

Unlock the Full CI Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis